aid
first
recogn
new
distinct
clinic
entiti
gottlieb
et
al
masur
et
al
siegal
et
al
first
case
recogn
unusu
cluster
diseas
kaposi
sarcoma
pneumocysti
carinii
pneumonia
pcp
young
homosexu
men
although
unusu
diseas
previous
observ
distinct
subgroup
popul
older
men
mediterranean
origin
case
kaposi
sarcoma
sever
immunosuppress
cancer
patient
case
pcp
occurr
diseas
previous
healthi
young
peopl
unpreced
sinc
first
case
newli
defin
clinic
syndrom
involv
homosexu
men
lifestyl
practic
first
implic
intens
investig
includ
exposur
amyl
butyl
nitrat
popper
frequent
contact
sperm
rectal
sex
might
act
immunostimulatori
dose
foreign
protein
antigen
howev
aid
case
soon
report
popul
well
includ
inject
drug
user
idu
anonym
hemophiliac
davi
et
al
poon
et
al
elliott
et
al
similar
investig
male
homosexu
popul
new
risk
group
expos
dose
foreign
protein
antigen
blood
case
idu
would
occur
intraven
inject
drug
needl
share
case
hemophiliac
therapeut
infus
factor
viii
asymptomat
hemophiliac
idu
often
found
unusu
immunolog
test
invert
lymphocyt
helper
suppressor
ratio
ie
less
normal
ratio
helper
suppressor
cell
abnorm
test
suggest
problem
cellular
immun
system
low
number
helper
lymphocyt
also
refer
lymphocyt
find
similar
observ
mani
aid
patient
three
new
categori
aid
patient
soon
observ
includ
blood
transfus
recipi
curran
et
al
jaff
et
al
adult
central
africa
clumeck
et
al
piot
et
al
van
de
perr
et
al
infant
born
mother
aid
idu
rubinstein
et
al
olesk
et
al
scott
et
al
transfusionassoci
case
receiv
blood
donat
aid
patient
least
three
year
began
show
symptom
curran
et
al
jaff
et
al
base
dispar
popul
afflict
new
maladi
emerg
epidemiolog
diseas
possibl
infecti
etiolog
aid
consid
franci
et
al
multipl
studi
initi
determin
possibl
role
variou
microorgan
especi
virus
caus
aid
studi
measur
compar
seropreval
rate
suspect
virus
aid
patient
control
shortlist
candid
virus
includ
cytomegaloviru
alreadi
associ
immunosuppress
kidney
transplant
patient
epsteinbarr
viru
lymphotrop
viru
hepat
b
viru
known
occur
elev
rate
homosexu
men
recipi
blood
blood
product
howev
base
uniqu
clinic
syndrom
unusu
epidemiolog
aid
one
virus
etiolog
involv
would
presum
newli
mutat
recombin
genet
variant
time
group
gallo
colleagu
gelmann
et
al
montagni
colleagu
barresinoussi
et
al
postul
variant
lymphotrop
retroviru
htlv
might
etiolog
agent
aid
inde
htlv
discov
gallo
colleagu
human
viru
known
infect
helper
lymphocyt
time
poiesz
et
al
seem
reason
sinc
alreadi
clear
helper
lymphocyt
select
deplet
caus
agent
clinic
aid
rubinstein
et
al
ammann
et
al
fahey
et
al
lane
et
al
addit
htlv
known
transmit
rout
etiolog
agent
aid
sexual
contact
transmiss
appar
effici
male
blood
mother
babi
essex
final
htlvi
also
known
induc
immunosuppress
essex
et
al
previous
recogn
anim
retroviru
system
essex
et
al
aid
patient
blood
sampl
repeatedli
cultur
attempt
find
viru
relat
htlvi
htlvii
kalyanaraman
et
al
although
antibodi
crossreact
htlvi
htlvrelat
genom
sequenc
found
minor
aid
patient
gelmann
et
al
barresinoussi
et
al
essex
et
al
reactiv
weak
suggest
either
aid
patient
also
infect
htlv
distant
weakli
reactiv
viru
caus
agent
soon
gallo
colleagu
obtain
proof
aid
link
htlv
gallo
et
al
schupbach
et
al
character
agent
term
reveal
isol
detect
earlier
montagni
colleagu
barresinoussi
et
al
despit
controversi
name
ident
certain
isol
new
uniqu
human
pathogen
clearli
distant
genet
rel
known
htlv
viru
may
recent
introduc
human
primat
reservoir
essex
kanki
recogn
caus
aid
also
recogn
viru
new
least
inhabit
western
hemispher
rais
question
whether
also
new
old
world
human
popul
africa
whether
recent
enter
human
anoth
speci
report
diseas
aid
report
popul
conceiv
present
africa
time
interplay
pathogen
host
would
led
less
virul
viru
peopl
genet
resist
lethal
properti
viru
howev
earli
clinic
studi
indic
differ
pathogen
virushost
interact
africa
compar
unit
state
europ
relat
viru
like
present
human
popul
central
africa
time
even
aid
diagnos
unit
state
earli
african
resid
europ
present
similar
clinic
sign
symptom
aid
clumeck
et
al
serum
sampl
collect
african
earlier
period
also
examin
presenc
antibodi
reactiv
case
examin
store
sampl
suggest
elev
rate
infect
africa
saxing
et
al
subsequ
reveal
survey
conduct
firststag
test
imperfect
addit
reactor
mostli
fals
posit
due
either
contamin
hiv
antigen
sticki
sera
contain
antibodi
react
nonspecif
sera
repeatedli
frozen
thaw
maintain
poor
condit
examin
sera
taken
africa
period
found
one
antibodyposit
sampl
clearli
posit
specif
manner
nahmia
et
al
test
highli
specif
test
radioimmunoprecipit
sampl
contain
high
titer
antibodi
reactiv
virtual
major
antigen
sampl
repres
rare
posit
reactor
highrisk
group
individu
suffer
tuberculosi
aidslik
ill
region
subsequ
high
rate
infect
howev
per
cent
fewer
individu
test
posit
classifi
region
moder
high
preval
kinshasa
zair
suggest
viru
rare
present
place
would
classifi
within
aid
belt
africa
recognit
aid
caus
hiv
easi
accept
small
group
scientist
persist
denial
overwhelm
evid
causat
addit
variou
conspiraci
theori
emerg
suggest
deliber
creat
germ
warfar
scientist
proclam
seem
silli
irrat
inform
medic
scientist
interfer
construct
attempt
educ
appropri
popul
group
one
reason
reluct
accept
aid
infecti
diseas
caus
prolong
induct
period
combin
high
mortal
rate
infecti
diseas
occur
short
induct
period
even
small
number
infecti
diseas
long
induct
period
caus
virus
tropic
spastic
paraparesi
adult
cell
leukemia
shingl
small
fraction
infect
peopl
experi
clinic
outcom
definit
aid
amalgam
clinic
outcom
rang
tuberculosi
chronic
diarrhea
cancer
eg
lymphoma
kaposi
sarcoma
also
may
caus
confus
tri
accept
singl
etiolog
caus
becom
logic
recogn
aid
diseas
fundament
irrevers
destruct
immun
system
outcom
secondari
immun
destruct
anoth
problem
understand
aid
etiolog
may
lack
appreci
disciplin
epidemiolog
dissens
proper
definit
caus
epidemiologist
highrisk
associ
tobacco
lung
cancer
suffici
ascrib
caus
use
analog
logic
causal
associ
infect
subsequ
destruct
immun
system
overwhelm
prospect
cohort
studi
almost
peopl
eventu
develop
immun
deplet
associ
much
higher
viral
infect
polio
flu
concern
time
spatial
geograph
associ
clinic
aid
rate
exactli
parallel
hiv
infect
rate
whether
bombay
san
francisco
nairobi
allow
induct
period
recent
lack
understand
caus
immun
deplet
help
reject
epidemiolog
deni
causat
situat
chang
dramat
howev
recognit
highli
lytic
lymphocyt
yu
et
al
larg
number
cell
kill
viru
vivo
wei
et
al
ho
et
al
low
rate
infect
circul
lymphocyt
interpret
incompat
destruct
larg
number
cell
recent
studi
reveal
lymph
node
rather
blood
per
cent
lymph
node
cell
may
infect
pantaleo
et
al
also
highli
unusu
viru
target
lymphocyt
macrophag
essenti
compon
immun
system
final
transmit
exactli
way
clinic
aid
blood
sex
mother
infant
taken
togeth
variou
correl
provid
inescap
evid
must
caus
aid
soon
recognit
clinic
aid
peopl
sever
clinic
report
describ
outbreak
sever
infect
wast
diseas
death
sever
coloni
asian
macaqu
monkey
hous
primat
center
unit
state
letvin
et
al
henrickson
et
al
due
similar
human
syndrom
diseas
design
simian
aid
said
case
human
aid
mani
possibl
caus
consid
follow
recognit
said
appear
infecti
origin
cytomegaloviru
monkey
also
consid
possibl
etiolog
agent
howev
seroepidemiolog
screen
reveal
proport
said
monkey
antibodi
crossreact
hiv
kanki
et
al
b
healthi
monkey
antibodi
although
antibodi
crossreact
core
antigen
show
weak
crossreact
envelop
antigen
character
cultur
reveal
presenc
hivlik
particl
antigen
detect
antibodi
phylli
j
kanki
myron
e
essex
either
said
monkey
peopl
aid
size
protein
antigen
detect
radioimmunoprecipit
analysi
similar
antigen
test
sera
peopl
aid
healthi
carrier
virtual
sera
antibodi
crossreact
core
antigen
primat
viru
name
stlviii
due
relationship
call
htlviii
andor
lav
later
term
simian
immunodefici
viru
siv
biberfeld
et
al
anim
model
aid
import
advanc
time
particularli
given
close
similar
diseas
anim
host
howev
origin
viru
remain
puzzl
although
case
aid
report
africa
time
aid
case
asia
consid
quit
rare
test
hypothesi
natur
primat
host
siv
would
abl
sustain
infect
without
signific
diseas
primat
would
like
resid
africa
least
half
healthi
wildcaught
african
green
monkey
show
evid
exposur
siv
basi
antibodi
kanki
et
al
kanki
et
al
although
possibl
siv
caus
type
diseas
recogn
clear
diseas
resembl
lethal
immunosuppress
syndrom
found
asian
macaqu
monkey
similarli
captiv
african
mangabey
monkey
infect
siv
reveal
diseas
symptom
pathogen
effect
siv
appear
speciesspecif
studi
wildcaught
asian
monkey
demonstr
siv
natur
infect
primat
gener
believ
siv
introduc
asian
macaqu
captiv
explain
part
unusu
high
mortal
induc
siv
recent
studi
reveal
sever
african
monkey
speci
infect
differ
siv
includ
sever
speci
commonli
describ
african
green
vervet
grivet
sabaeu
tantalu
well
mona
diana
syke
mandril
sooti
mangabey
speci
tsujimoto
et
al
johnson
et
al
allan
et
al
thu
far
siv
describ
asian
speci
baboon
though
speci
infect
captiv
primat
lentivirus
group
siv
close
relat
although
mandril
siv
evolutionarili
distant
tsujimoto
et
al
sooti
mangabey
monkey
viru
senegales
human
hand
essenti
genet
level
peeter
et
al
essex
kirchhoff
et
al
viru
also
appar
accident
infect
asian
macaqu
captiv
essex
kanki
possibl
siv
might
caus
diseas
rare
african
monkey
advanc
age
could
rule
high
preval
infect
wildcaught
monkey
support
notion
african
speci
primat
evolv
benign
coexist
viru
infect
affect
surviv
clearli
differ
case
siv
asian
primat
peopl
wild
macaqu
appear
infect
siv
viru
limit
african
primat
appear
like
viru
accident
infect
captiv
rhesu
monkey
recent
time
new
siv
still
describ
possibl
speci
specif
may
play
role
level
hostviru
adapt
therefor
level
popul
infect
georgescourbot
et
al
current
appear
natur
siv
infect
african
primat
result
signific
diseas
support
high
seropreval
rate
speci
evalu
thu
appear
virushost
interact
result
nonpathogen
infect
genet
immunolog
viru
determin
relationship
worthi
studi
could
specul
viru
either
move
subhuman
primat
peopl
prior
introduc
citi
migrat
resist
carrier
previous
isol
group
peopl
howev
present
rural
area
might
expect
find
african
demonstr
greater
resist
infect
diseas
develop
owe
genet
select
evolut
human
speci
prospect
studi
conduct
date
african
infect
appear
develop
clinic
aid
sign
symptom
hiv
diseas
rapidli
individu
unit
state
europ
mann
et
al
marlink
et
al
furthermor
degre
genom
variat
seen
african
isol
greater
seen
virus
europ
unit
state
viru
could
progenitor
isol
chimpanze
central
africa
huet
et
al
find
combin
knowledg
virus
test
appear
avirul
inocul
chimpanze
also
compat
subhuman
primat
origin
african
isol
appear
close
chimpanze
isol
prototyp
strain
de
ley
et
al
zekeng
et
al
find
appear
confirm
detail
genet
analysi
viru
chimpanze
hous
unit
state
although
exact
histori
pedigre
anim
unclear
gao
et
al
rel
siv
found
wild
african
monkey
per
cent
relat
genom
level
seem
logic
virus
highli
relat
siv
might
also
present
human
popul
serum
sampl
west
african
prostitut
examin
determin
antibodi
highli
crossreact
siv
barin
et
al
western
blot
radioimmunoprecipit
method
becam
clear
signific
proport
senegales
prostitut
antibodi
highli
reactiv
major
antigen
siv
detect
techniqu
siv
antigen
react
sera
individu
either
european
central
african
origin
classic
diseas
manifest
aid
littl
reaction
seen
envelop
antigen
class
reactiv
seen
serum
sampl
west
african
prostitut
fact
virtual
indistinguish
seen
serum
sampl
african
monkey
captiv
rhesu
macaqu
kanki
et
al
hirsch
et
al
essex
hiv
viru
lifecycl
requir
transcript
viral
rna
dna
copi
becom
randomli
integr
host
cellular
dna
transcript
process
perform
viru
enzym
revers
transcriptas
errorpron
result
round
replic
result
least
one
mutat
per
genom
copi
genet
variat
hiv
hierarch
depict
simplifi
schemat
subtyp
variat
interpati
variat
intrapati
variat
figur
viru
isol
north
american
european
show
distinct
genet
variabl
compar
variabl
virus
african
patient
burk
mccutchan
variabl
dramat
recogn
genet
variabl
viral
isol
singl
geograph
region
ie
interisol
variabl
myer
pavlaki
korber
et
al
turn
also
distinguish
genet
variat
seen
level
individu
patient
ie
intrapati
variabl
level
individu
patient
swarm
quasispeci
highli
relat
distinguish
viral
variant
demonstr
throughout
cours
hiv
infect
goodenow
et
al
balf
et
al
delassu
et
al
genet
divers
therefor
major
characterist
hiv
virus
provid
major
obstacl
drug
vaccin
develop
remark
isol
unit
state
western
europ
singl
subtyp
b
divers
subtyp
found
subsaharan
africa
subtyp
c
particular
found
frequent
subtyp
africa
high
rate
spread
africa
appear
time
epidem
spread
unit
state
europ
movement
popul
extens
intern
travel
make
likelihood
mix
subtyp
inevit
nonb
subtyp
alreadi
identifi
increas
unit
state
europ
asia
introduct
spread
appear
decad
later
west
see
chapter
detail
thailand
subtyp
b
detect
intraven
drug
user
late
subtyp
e
first
detect
earli
subtyp
e
spread
rapidli
throughout
heterosexu
thailand
highest
rate
northern
region
countri
wenig
et
al
although
appar
present
earlier
region
subtyp
b
never
spread
caus
major
heterosexu
epidem
subtyp
e
china
epidem
idu
uniqu
recombin
viru
c
b
heterosexu
popul
subtyp
e
appear
predomin
subtyp
similar
much
southeast
asia
complex
mixtur
subtyp
asia
challeng
vaccin
develop
effort
sinc
distinct
subtyp
epidem
observ
differ
highrisk
popul
similar
situat
occur
india
subtyp
b
c
subtyp
b
appear
introduc
earlier
among
idu
subtyp
spread
rapidli
among
heterosexu
subtyp
c
previous
associ
massiv
heterosexu
epidem
southeastern
africa
subtyp
c
also
caus
rapid
heterosexu
epidem
western
india
initi
spread
bombay
region
jain
et
al
wenig
et
al
past
year
clear
subtyp
c
sole
viral
subtyp
respons
newest
perhap
frighten
hiv
epidem
worldwid
countri
southern
africa
rapid
dissemin
hiv
infect
describ
rate
rang
per
cent
pregnant
women
countri
region
result
signific
increas
subtyp
c
infect
africa
predomin
place
india
perhap
china
viral
subtyp
respons
half
hiv
infect
worldwid
unaid
even
distant
subtyp
design
hivo
detect
cameroon
nkengasong
et
al
virus
isol
subtyp
even
less
relat
subtyp
h
either
subtyp
relat
yet
hivo
relat
emphas
distanc
subtyp
h
design
major
group
hivo
design
outgroup
charneau
et
al
despit
extens
serosurvey
distribut
hivo
appear
quit
restrict
peeter
et
al
subtyp
h
probabl
common
human
progenitor
ancestor
hivo
doubt
enter
independ
chimpanze
host
almost
certainli
enter
independ
monkey
speci
nativ
west
africa
essex
kanki
hirsch
et
al
movement
distribut
subtyp
throughout
world
often
perplex
particularli
subtyp
e
h
appear
isol
frequent
place
asia
south
america
eastern
europ
africa
presum
origin
louwagi
et
al
bobkov
et
al
howev
virus
isol
character
acquir
analysi
conveni
sampl
therefor
may
suffer
extens
region
select
bia
inadvert
cluster
futur
import
develop
consist
surveil
method
fulllength
sequenc
analysi
gener
true
global
map
hiv
subtyp
understand
epidemiolog
biolog
differ
subtyp
critic
futur
intervent
effort
studi
clearli
need
anderson
et
al
studi
demonstr
differ
abil
nonb
b
subtyp
virus
infect
langerhan
cell
critic
cell
heterosexu
transmiss
hiv
suggest
viral
properti
nonb
subtyp
virus
would
facilit
heterosexu
transmiss
may
contribut
dramat
epidem
spread
asia
africa
sotoramirez
et
al
crosssect
studi
heterosexu
coupl
thailand
suggest
higher
risk
heterosexu
transmiss
subtyp
e
compar
subtyp
b
kunanusont
et
al
studi
mani
african
countri
describ
multipl
subtyp
known
subtyp
enter
popul
differ
time
point
distribut
subtyp
reflect
dynam
differ
subtypespecif
transmiss
potenti
studi
south
africa
demonstr
associ
certain
subtyp
differ
mode
hiv
transmiss
subtyp
b
virus
associ
homosexu
transmiss
nonb
subtyp
associ
heterosexu
transmiss
vanharmelen
et
al
futur
detail
studi
prospect
follow
cohort
necessari
determin
differ
pathogen
transmiss
differ
subtyp
host
select
effici
heterosexu
transmiss
may
partial
explain
high
rate
heterosexu
transmiss
seen
subtyp
c
e
sotoramirez
et
al
subtyp
b
major
subtyp
develop
world
appear
undergon
counterselect
ie
less
like
select
compar
virul
transmiss
virus
lose
phenotyp
properti
effici
heterosexu
transmiss
effici
heterosexu
transmiss
requir
particular
genotyp
vagin
infect
sequenc
may
partial
lost
b
strain
repeatedli
passag
blood
exposur
rectal
intercours
mani
nonb
subtyp
hand
could
theoret
maintain
vagin
phenotyp
properti
regular
heterosexu
transmiss
africa
asia
kunanusont
et
al
sotoramirez
et
al
base
prospect
studi
femal
sex
worker
dakar
seneg
recent
report
diseas
progress
nonb
subtyp
infect
known
time
infect
evalu
aidsfre
surviv
curv
women
incid
subtyp
c
g
infect
shown
distinct
differ
aidsfre
surviv
kanki
et
al
comparison
nona
subtyp
subtyp
demonstr
significantli
longer
aidsfre
surviv
women
infect
subtyp
due
small
sampl
size
per
subtyp
estim
aid
incid
consid
imprecis
studi
clearli
warrant
crosssect
studi
indic
signific
proport
aid
case
subtyp
infect
west
east
africa
pj
kanki
unpublish
data
studi
subtyp
natur
histori
progress
differ
geograph
region
clearli
need
better
evalu
role
viral
subtyp
differ
aid
pathogenesi
human
immunodefici
viru
infect
result
progress
loss
immun
function
mark
deplet
lymphocyt
lead
opportunist
infect
malign
characterist
syndrom
term
aid
number
host
viral
factor
influenc
rate
diseas
progress
studi
west
prior
implement
antiretrovir
therapi
suggest
median
time
aid
rang
year
histor
lymphocyt
count
provid
reliabl
prognost
marker
hiv
progress
fahey
et
al
addit
prognost
marker
progress
aid
includ
immunolog
marker
immun
dysfunct
includ
cutan
anergi
redfield
et
al
blatt
et
al
serum
neopterin
level
fahey
et
al
past
quantit
viral
infect
perform
imperfect
andor
labori
method
serolog
quantit
viral
core
antigen
frequent
consid
surrog
marker
high
viral
burden
allain
et
al
dewolf
et
al
quantit
viral
cultur
difficult
perform
cost
effect
clinic
monitor
regular
basi
coomb
et
al
ho
et
al
hiv
viral
express
measur
mrna
also
consid
import
marker
preced
immunolog
compromis
gupta
et
al
saksela
et
al
qualit
characterist
hiv
viru
infect
includ
syncytiuminduc
properti
viru
often
coupl
viral
burden
syncytiuminduc
virus
associ
high
viral
load
rapid
progress
nonsyncytiuminduc
virus
associ
lower
viru
load
slow
progress
tersmett
et
al
fenyo
et
al
develop
sensit
pcrbase
technolog
reliabl
quantit
rna
level
viru
plasma
revolution
abil
track
viral
infect
pcr
technolog
base
use
temperaturesensit
dna
polymeras
target
sequenc
identifi
dna
sequenc
appropri
primer
design
span
sequenc
interest
primer
need
similar
origin
target
sequenc
possibl
primer
anneal
target
sequenc
temperaturesensit
polymeras
begin
transcrib
sequenc
match
sequenc
found
sampl
temperatur
increas
strand
dna
separ
primer
bind
polymeras
reaction
occur
way
larg
number
exact
dna
copi
made
given
cycl
temperatur
avail
primer
nucleotid
polymeras
minut
copi
dna
detect
larg
volum
dna
sensit
technolog
mellor
colleagu
provid
import
new
evid
quantit
plasma
level
rna
viru
viral
load
import
predictor
diseas
progress
mellor
et
al
base
larg
us
cohort
studi
homosexu
men
risk
develop
aid
death
significantli
associ
baselin
plasma
viral
load
independ
lymphocyt
count
mellor
et
al
mellor
et
al
worth
note
studi
mani
ensu
viral
load
studi
conduct
us
europ
subtyp
b
infect
predomin
viral
load
studi
discuss
critic
consid
popul
studi
hiv
viral
subtyp
methodolog
employ
mani
studi
follow
natur
histori
hiv
infect
time
report
util
viral
load
determin
track
predict
diseas
progress
sinc
varieti
marker
notabl
lymphocyt
subset
data
frequent
avail
relationship
viral
load
lymphocyt
count
regularli
evalu
import
evalu
viral
load
predict
valu
full
cours
hiv
natur
histori
requir
analysi
longstand
cohort
studi
time
infect
known
observ
time
predat
use
antiretrovir
therapi
larg
us
multicent
aid
cohort
studi
mac
demonstr
strong
correl
initi
hiv
rna
load
declin
lymphocyt
count
initi
hiv
rna
level
slope
associ
aidsfre
time
hiv
rna
load
first
seroposit
visit
similar
three
month
seroconvers
highli
predict
aid
subsequ
hiv
rna
measur
show
even
better
prognost
discrimin
howev
hiv
rna
slope
three
year
preced
aid
hiv
rna
level
aid
diagnosi
show
littl
variat
accord
total
aidsfre
time
lyle
et
al
mac
studi
popul
larg
white
homosexu
male
cohort
may
possibl
gener
find
popul
group
differ
mode
transmiss
differ
viral
subtyp
sabin
colleagu
report
similar
predict
valu
plasma
viral
load
larg
european
hemophilia
cohort
result
confirm
import
hiv
rna
level
assess
longterm
prognosi
individu
infect
hiv
sabin
et
al
risk
develop
aid
death
remain
low
rna
level
log
copiesml
increas
rapidli
thereaft
support
current
guidelin
initi
antiretrovir
therapi
viral
load
exceed
level
sabin
et
al
french
seroco
studi
hiv
seroconvert
n
patient
remain
aidsfre
lower
earli
viral
load
averag
longer
period
viral
load
declin
infect
versu
month
follow
slower
viral
load
increas
compar
progress
aid
hubert
et
al
true
plateauphas
seroconvers
period
observ
last
approxim
four
year
identifi
patient
remain
aidsfre
least
month
multivari
analysi
earli
viral
load
later
chang
signific
predictor
progress
aid
hubert
et
al
recent
year
studi
primari
hiv
infect
learn
degre
viru
contain
occur
earli
phase
hiv
infect
vivo
critic
period
complex
dynam
infect
viru
respond
host
immun
factor
lead
establish
level
viremia
viral
setpoint
appear
predict
subsequ
hiv
progress
rate
surviv
mellor
et
al
mellor
et
al
incub
period
initi
infect
onset
symptom
averag
day
sd
day
rang
day
selflimit
ill
resolv
within
week
current
data
suggest
hiv
viral
load
blood
reach
peak
first
day
concurr
precipit
drop
cell
count
increas
absolut
number
lymphocyt
clark
et
al
clark
shaw
clark
wolther
subsequ
earli
event
tie
resolut
acut
clinic
syndrom
lower
hiv
load
rebound
lymphocyt
level
corey
colleagu
report
consider
variabl
viral
burden
earli
phase
hiv
infect
day
acquisit
follow
rapid
decreas
plasma
hiv
rna
level
inflect
point
gradual
increas
schacker
et
al
earli
infect
phase
continu
next
month
seed
establish
hiv
viral
load
blood
lymphoreticular
tissu
fauci
fauci
hayn
et
al
establish
steadyst
viremia
viral
setpoint
attain
phase
infect
remain
rel
invari
throughout
much
long
incub
period
well
establish
level
plasma
viremia
earli
infect
highli
predict
futur
clinic
cours
mellor
et
al
mellor
et
al
stein
et
al
crosssect
studi
longterm
nonprogressor
ltnp
group
demonstr
significantli
lower
cell
plasma
viral
burden
compar
rapid
progressor
cao
et
al
rinaldo
et
al
pantaleo
et
al
increas
plasma
viremia
correl
increas
provir
burden
quantit
viru
isol
quantiti
viru
lymphoreticular
tissu
hayn
et
al
stabil
virionassoci
rna
level
suggest
equilibrium
replic
rate
efficaci
immunolog
respons
establish
shortli
infect
persist
throughout
asymptomat
period
diseas
thu
defect
immunolog
control
infect
may
import
viral
replic
rate
determin
aidsfre
surviv
infect
treatment
highli
activ
antiretrovir
therapi
haart
shown
drastic
lower
plasma
viremia
current
use
indic
effect
treatment
obrien
et
al
panther
et
al
discontinu
haart
individu
rebound
viral
burden
approxim
prehaart
level
even
signific
laps
time
approach
five
year
hatano
et
al
addit
viral
load
baselin
predict
rate
declin
follow
antiretrovir
therapi
noterman
et
al
multipl
studi
shown
current
repertoir
antiretrovir
drug
insuffici
complet
erad
infect
individu
wong
et
al
finzi
et
al
dornadula
et
al
era
hiv
treatment
use
sequenti
hiv
rna
measur
may
meaning
singl
measur
pretreat
slope
rna
declin
acut
infect
individu
increas
significantli
p
initi
antiretrovir
therapi
howev
posttreat
slope
lower
found
chronic
infect
individu
p
slope
invers
correl
p
baselin
rna
putter
et
al
combin
multipl
advers
sideeffect
associ
haart
stringent
demand
regimen
adher
prompt
design
new
treatment
strategi
sever
studi
examin
longitudin
effect
multipl
schedul
treatment
interrupt
longterm
safeti
experiment
protocol
larg
unknown
particularli
respect
gener
resist
virus
howev
treatment
strategi
would
improv
likelihood
longterm
adher
use
individu
viral
load
plateau
serv
import
guid
aggress
time
treatment
interrupt
hatano
et
al
two
decad
world
come
recogn
uniqu
pathogen
new
viru
earli
epidemiolog
pattern
hivaid
epidem
present
uniqu
challeng
virologist
epidemiologist
clinician
public
health
offici
throughout
histori
epidem
continu
challeng
us
within
respect
disciplin
mani
way
promot
integr
field
effort
curb
spread
although
discoveri
new
pathogen
occur
rel
quickli
first
case
still
mani
question
chronic
viru
infect
uniformli
virul
year
post
infect
mani
mysteri
still
surround
origin
hiv
viru
rel
preval
relat
simian
virus
african
primat
high
suggest
ancient
stabl
virushost
relationship
one
develop
virtual
innocu
viru
infect
intermedi
viru
significantli
less
pathogen
take
year
develop
aid
although
endstag
diseas
appear
similar
still
tri
discov
viral
host
mechan
viru
abl
persist
long
period
time
asymptomat
phase
yet
somehow
trigger
caus
fatal
immunosuppress
decad
later
molecular
techniqu
pcr
diagnost
highthroughput
sequenc
appreci
genet
divers
hiv
siv
decad
ago
would
take
month
gener
analyz
sequenc
singl
hiv
viru
feat
readili
achiev
day
also
seen
technolog
brought
bear
epidem
infecti
diseas
recent
sever
acut
respiratori
syndrom
sar
epidem
asia
doubt
new
techniqu
expedit
character
everchang
hiv
epidem
assist
research
predict
viral
genotyp
relev
target
genet
divers
viru
level
infect
individu
appreci
quasispeci
rather
singl
genotyp
continu
challeng
immun
system
clearli
play
role
pathogen
viru
also
present
signific
barrier
current
armamentarium
antiretrovir
drug
provid
patient
emerg
viral
resist
variant
may
continu
requir
better
differ
therapi
control
viru
infect
long
term
present
therapi
affect
cure
variou
viral
reservoir
signific
viral
replic
rate
suggest
nearli
imposs
near
futur
genet
divers
hiv
evidenc
differ
strain
subtyp
yield
complex
global
map
variant
virus
affect
abil
diagnos
treat
ultim
vaccin
everchang
set
virus
alreadi
recogn
subtyp
infect
singl
popul
gener
recombin
virus
incred
rate
might
predict
vaccin
develop
may
never
keep
pace
provid
steril
immun
new
technolog
made
signific
advanc
research
better
understand
control
viru
abil
measur
viral
load
revolution
abil
track
viru
infect
replic
patient
advent
viral
load
assay
technolog
well
pragmat
feat
suppli
sturdi
clinic
measur
manag
aid
patient
formerli
clinician
scientist
reli
difficult
cumbersom
plasma
peripher
blood
mononuclear
cell
cultur
viru
isol
antigen
quantit
monitor
infect
individu
patient
develop
pcrbase
method
measur
viral
rna
particularli
use
follow
patient
therapeut
manag
importantli
measur
viral
burden
provid
new
insight
mechan
hiv
transmiss
pathogenesi
twentyfirst
centuri
doubt
bring
new
technolog
research
advanc
hivaid
research
past
year
seen
global
commun
least
acknowledg
inequ
hivaid
global
epidem
renew
interest
support
prevent
treatment
vaccin
direct
develop
world
hivaid
epidem
complex
virolog
point
view
multipl
subtyp
type
hiv
virus
evergrow
proport
complex
recombin
need
test
hiv
intervent
vaccin
part
world
therefor
critic
sinc
effect
hivaid
epidem
popul
largest
impact
scientist
need
continu
effort
insur
good
scienc
public
health
effect
health
polici
end
hivaid
epidem
next
centuri
